ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

PLSE Pulse Biosciences Inc

6.86
0.17 (2.54%)
Last Updated: 12:12:56
Delayed by 15 minutes

Period:

Draw Mode:

Volume 26,082
Bid Price 6.84
Ask Price 6.89
News -
Day High 6.91

Low
3.78

52 Week Range

High
13.62

Day Low 6.65
Company Name Stock Ticker Symbol Market Type
Pulse Biosciences Inc PLSE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.17 2.54% 6.86 12:12:56
Open Price Low Price High Price Close Price Prev Close
6.71 6.65 6.91 6.69
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
248 26,082 $ 6.78 $ 176,749 - 3.78 - 13.62
Last Trade Time Type Quantity Stock Price Currency
12:15:51 14 $ 6.85 USD

Pulse Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
376.14M 54.99M - 0 -42.21M -0.77 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pulse Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PLSE Message Board. Create One! See More Posts on PLSE Message Board See More Message Board Posts

Historical PLSE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.267.596.5956.92128,274-0.40-5.51%
1 Month7.6968.346.5957.51188,945-0.836-10.86%
3 Months8.9511.63986.5958.70165,686-2.09-23.35%
6 Months4.0113.623.789.02231,8532.8571.07%
1 Year5.8713.623.787.85198,5810.9916.87%
3 Years21.0229.161.187.25153,651-14.16-67.36%
5 Years16.4745.821.189.76128,119-9.61-58.35%

Pulse Biosciences Description

Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems.

Your Recent History

Delayed Upgrade Clock